NOT FOR DISTRIBUTION
Header cover image

Fresenius SE KGaA

Market Cap

€21.5b

Last Updated

2021/04/14 19:12 UTC

Data Sources

Company Financials +

Executive Summary

Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care Germany and internationally. More Details


Snowflake Analysis

Undervalued established dividend payer.


Similar Companies

Share Price & News

How has Fresenius SE KGaA's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: FREA is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: FREA's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

1.1%

FREA

0.9%

DE Healthcare

0.2%

DE Market


1 Year Return

4.3%

FREA

0.6%

DE Healthcare

42.4%

DE Market

Return vs Industry: FREA underperformed the German Healthcare industry which returned 0.6% over the past year.

Return vs Market: FREA underperformed the German Market which returned 42.4% over the past year.


Shareholder returns

FREAIndustryMarket
7 Day1.1%0.9%0.2%
30 Day5.5%5.2%5.1%
90 Day0%-2.9%9.6%
1 Year5.9%4.3%2.6%0.6%47.0%42.4%
3 Year-39.1%-41.1%-27.9%-31.4%23.5%12.8%
5 Year-37.9%-40.6%-28.5%-33.1%51.0%29.5%

Long-Term Price Volatility Vs. Market

How volatile is Fresenius SE KGaA's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Fresenius SE KGaA undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: FREA (€9.55) is trading below our estimate of fair value (€32.05)

Significantly Below Fair Value: FREA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: FREA is good value based on its PE Ratio (12.7x) compared to the DE Healthcare industry average (32.5x).

PE vs Market: FREA is good value based on its PE Ratio (12.7x) compared to the German market (28.2x).


Price to Earnings Growth Ratio

PEG Ratio: FREA is poor value based on its PEG Ratio (1.4x)


Price to Book Ratio

PB vs Industry: FREA is good value based on its PB Ratio (1.3x) compared to the DE Healthcare industry average (1.7x).


Future Growth

How is Fresenius SE KGaA forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?

9.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FREA's forecast earnings growth (9% per year) is above the savings rate (0.07%).

Earnings vs Market: FREA's earnings (9% per year) are forecast to grow slower than the German market (20.9% per year).

High Growth Earnings: FREA's earnings are forecast to grow, but not significantly.

Revenue vs Market: FREA's revenue (4.8% per year) is forecast to grow slower than the German market (5.4% per year).

High Growth Revenue: FREA's revenue (4.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: FREA's Return on Equity is forecast to be low in 3 years time (10.5%).


Past Performance

How has Fresenius SE KGaA performed over the past 5 years?

5.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: FREA has high quality earnings.

Growing Profit Margin: FREA's current net profit margins (4.7%) are lower than last year (5.3%).


Past Earnings Growth Analysis

Earnings Trend: FREA's earnings have grown by 5.4% per year over the past 5 years.

Accelerating Growth: FREA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: FREA had negative earnings growth (-9.4%) over the past year, making it difficult to compare to the Healthcare industry average (2%).


Return on Equity

High ROE: FREA's Return on Equity (10.8%) is considered low.


Financial Health

How is Fresenius SE KGaA's financial position?


Financial Position Analysis

Short Term Liabilities: FREA's short term assets (€15.8B) exceed its short term liabilities (€13.2B).

Long Term Liabilities: FREA's short term assets (€15.8B) do not cover its long term liabilities (€27.4B).


Debt to Equity History and Analysis

Debt Level: FREA's debt to equity ratio (75.8%) is considered high.

Reducing Debt: FREA's debt to equity ratio has reduced from 77.9% to 75.8% over the past 5 years.

Debt Coverage: FREA's debt is well covered by operating cash flow (33.2%).

Interest Coverage: FREA's interest payments on its debt are well covered by EBIT (6.8x coverage).


Balance Sheet


Dividend

What is Fresenius SE KGaA current dividend yield, its reliability and sustainability?

2.25%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: FREA's dividend (2.27%) is higher than the bottom 25% of dividend payers in the German market (1.06%).

High Dividend: FREA's dividend (2.27%) is low compared to the top 25% of dividend payers in the German market (3.21%).


Stability and Growth of Payments

Stable Dividend: FREA's dividends per share have been stable in the past 10 years.

Growing Dividend: FREA's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (28.7%), FREA's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: FREA's dividends in 3 years are forecast to be well covered by earnings (25.3% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.0yrs

Average management tenure


CEO

Stephan Sturm (57 yo)

4.75yrs

Tenure

€6,061,000

Compensation

Mr. Stephan Sturm serves as Chairman of the Management Board, Chief Executive Officer and President at Fresenius Management SE, the General Partner of Fresenius SE & Co KGaA since July 1, 2016 and its Memb...


CEO Compensation Analysis

Compensation vs Market: Stephan's total compensation ($USD7.23M) is above average for companies of similar size in the German market ($USD5.22M).

Compensation vs Earnings: Stephan's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: FREA's management team is seasoned and experienced (6 years average tenure).


Board Members

Experienced Board: FREA's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Fresenius SE & Co. KGaA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Fresenius SE & Co. KGaA
  • Ticker: FREA
  • Exchange: DB
  • Founded: 1912
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: €21.541b
  • Shares outstanding: 557.54m
  • Website: https://www.fresenius.com

Number of Employees


Location

  • Fresenius SE & Co. KGaA
  • Else-Kröner-Strasse 1
  • Bad Homburg vor der Höhe
  • Hessen
  • 61352
  • Germany

Listings


Biography

Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care Germany and internationally. The company operates through four segments: Fr...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/14 19:12
End of Day Share Price2021/04/14 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.